Pliant Therapeutics (PLRX)
NASDAQ:PLRX
Want to see PLRX full AI Analyst Report?
Top Page
Pliant Therapeutics
(NASDAQ:PLRX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-24.81% Downside)
Action:Reiterated
Date:05/14/26
The score is primarily driven down by weak financial performance (no revenue, continued losses, and ongoing cash burn despite some improvement) and bearish technical momentum (price below key moving averages with negative MACD). Valuation is also constrained by negative earnings and lack of dividend support.
Positive Factors
Low Leverage
Pliant’s relatively low debt burden is a durable financial strength for a development-stage biotech: it lowers near-term default and interest risks, preserves access to credit or non-dilutive financing, and gives management flexibility to prioritize clinical programs without heavy fixed obligations.
Negative Factors
No Commercial Revenue
Absence of product revenue is a persistent structural risk: without commercial cash flow, the company must rely on financing or partnerships to fund operations, leaving long-term viability contingent on successful trials, approvals, and commercial launches rather than operating cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Pliant’s relatively low debt burden is a durable financial strength for a development-stage biotech: it lowers near-term default and interest risks, preserves access to credit or non-dilutive financing, and gives management flexibility to prioritize clinical programs without heavy fixed obligations.
Read all positive factors
Pliant Therapeutics (PLRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$74.30M
Dividend YieldN/A
Average Volume (3M)581.13K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue GrowthN/A
EPS Growth49.00%
CountryUS
Employees171
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.84
Shares Outstanding61,920,250
10 Day Avg. Volume902,150
30 Day Avg. Volume581,135
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.58
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-113.78
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$2.67Price Target Upside100.50% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Pliant Therapeutics Business Overview & Revenue Model
Company Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an ora...
How the Company Makes Money
Pliant Therapeutics does not have commercialized products and is primarily a development-stage company; as a result, it has historically generated little to no recurring product revenue. Its funding and any reported revenue typically come from (a)...
Pliant Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.58M | 9.69M | 7.57M |
| Gross Profit | -711.00K | -1.70M | 0.00 | 1.58M | 9.69M | 7.57M |
| EBITDA | -109.71M | -148.38M | -205.16M | -158.23M | -118.85M | -95.73M |
| Net Income | -113.22M | -149.34M | -210.30M | -161.34M | -123.32M | -97.26M |
Balance Sheet | ||||||
| Total Assets | 202.60M | 225.23M | 396.95M | 512.15M | 350.61M | 221.22M |
| Cash, Cash Equivalents and Short-Term Investments | 170.89M | 190.94M | 355.72M | 494.25M | 331.19M | 200.60M |
| Total Debt | 28.78M | 29.11M | 60.19M | 11.37M | 15.81M | 7.19M |
| Total Liabilities | 37.43M | 44.02M | 92.87M | 38.58M | 37.27M | 22.16M |
| Stockholders Equity | 165.17M | 181.21M | 304.08M | 473.58M | 313.34M | 199.06M |
Cash Flow | ||||||
| Free Cash Flow | -98.81M | -128.71M | -159.35M | -117.28M | -96.39M | -77.40M |
| Operating Cash Flow | -98.70M | -128.34M | -155.50M | -116.36M | -94.63M | -75.44M |
| Investing Cash Flow | 61.08M | 134.29M | 140.34M | -127.01M | -150.20M | 73.70M |
| Financing Cash Flow | -32.12M | -31.70M | 23.12M | 274.40M | 226.85M | 2.53M |
Pliant Therapeutics Technical Analysis
Neutral
1.33
Price Trends
1.26
Negative
1.26
Negative
1.40
Negative
Market Momentum
-0.03
Positive
47.16
Neutral
36.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLRX, the sentiment is Neutral. The current price of 1.33 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 1.26, and below the 200-day MA of 1.40, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 47.16 is Neutral, neither overbought nor oversold. The STOCH value of 36.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PLRX.
Pliant Therapeutics Risk Analysis
Pliant Therapeutics disclosed 83 risk factors in its most recent earnings report. Pliant Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pliant Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $175.16M | 0.90 | 43.14% | ― | -100.00% | ― | |
54 Neutral | $446.07M | -4.45 | -22.51% | ― | 1199.64% | 30.81% | |
53 Neutral | $176.39M | -2.46 | -91.12% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $17.60M | 0.04 | 7743.57% | ― | ― | 35.04% | |
45 Neutral | $130.25M | -9.06 | -61.43% | ― | -100.00% | 18.25% | |
44 Neutral | $74.30M | -0.97 | -59.06% | ― | ― | 49.00% |
* Healthcare Sector Average
PLRX
Pliant Therapeutics
1.20
-0.13
-9.77%
ORMP
Oramed Pharm
4.28
2.31
117.59%
OVID
Ovid Therapeutics
2.39
2.11
738.60%
IFRX
InflaRx
2.44
0.75
44.38%
EQ
Equillium
2.06
1.68
435.06%
QNCX
Quince Therapeutics
1.08
-9.22
-89.51%
Pliant Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Pliant Therapeutics Announces Board Retirements and Option Repricing
Neutral
Apr 17, 2026
Pliant Therapeutics announced that on April 14 and April 16, 2026, directors David E.I. Pyott and Katharine Knobil, M.D., notified the company of their plans to retire from its board and committees effective at the 2026 Annual Meeting of Stockhold...
Business Operations and StrategyPrivate Placements and Financing
Pliant Therapeutics Launches New $50 Million ATM Program
Neutral
Mar 30, 2026
On March 30, 2026, Pliant Therapeutics, Inc. entered into a new Sales Agreement with Leerink Partners LLC to establish an at-the-market equity program, allowing the company to sell up to $50 million of its common stock from time to time through th...
Business Operations and StrategyRegulatory Filings and Compliance
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration
Neutral
Mar 4, 2026
On March 3, 2026, Pliant Therapeutics, Inc. amended its Stockholder Rights Agreement with Computershare Trust Company, N.A., extending the final expiration of the shareholder rights from March 11, 2026, to March 11, 2027, while leaving other core ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.